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Foot-and-mouth disease virus (FMDV) is responsible for substantial economic losses in livestock breeding each year,
and the development of new strategies is needed to overcome the limitations of existing vaccines and antiviral
drugs. In this study, we evaluated the antiviral potential of transgenic porcine cells and suckling mice that
simultaneously expressed two short-hairpin RNAs (shRNAs) targeting the conserved regions of the viral polymerase
protein 3D and the non-structural protein 2B. First, two recombinant shRNA-expressing plasmids, PB-EN3D2B and
PB-N3D2B, were constructed and the efficiency of the constructs for suppressing an artificial target was
demonstrated in BHK-21 cells. We then integrated PB-EN3D2B into the genome of the porcine cell line IBRS-2 using
the piggyBac transposon system, and stable monoclonal transgenic cell lines (MTCL) were selected. Of the 6 MTCL
that were used in the antiviral assay, 3 exhibited significant resistance with suppressing ratios of more than 94% at
48 hours post-challenge (hpc) to both serotype O and serotype Asia 1 FMDV. MTCL IB-3D2B-6 displayed the
strongest antiviral activity, which resulted in 100% inhibition of FMDV replication until 72 hpc. Moreover, the
shRNA-expressing fragment of PB-N3D2B was integrated into the mouse genome by DNA microinjection to
produce transgenic mice. When challenged with serotype O FMDV, the offspring of the transgenic mouse lines
N3D2B-18 and N3D2B-81 exhibited higher survival rates of 19% to 27% relative to their non-transgenic littermates.
The results suggest that these heritable shRNAs were able to suppress FMDV replication in the transgenic cell lines
and suckling mice.Introduction
Foot-and-mouth disease (FMD) is a highly contagious
disease that affects more than 33 species of cloven-
hoofed animals, such as swine, cattle and other livestock
[1]. FMD outbreaks often cause severe economic losses
due to reduced productivity and the required slaughter
of millions of infected or susceptible animals, and these
outbreaks have even raised political disputes concerning
trade embargos on animal products. Therefore, this* Correspondence: liumq@fudan.edu.cn; ytzeng@stn.sh.cn
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reproduction in any medium, provided the ordisease is designated by the International Office of
Epizootics (OIE) as a serious disease that spreads rapidly
and requires socioeconomic considerations. The FMD
virus (FMDV) belongs to the genus Aphthovirus within
the family Picornaviridae [2]. The FMDV genome is
composed of a positive-sense, single-stranded RNA mo-
lecule of approximately 8500 nucleotides and contains a
unique large open reading frame.
The most commonly used strategies for controlling
FMD outbreaks are routine vaccination and slaughtering
of infected animals. However, livestock slaughter results
in substantial economic losses. The application of
inactivated and attenuated vaccines causes a risk for live
or revertant viruses to escape [3,4]. RNAi is a gene silen-
cing mechanism that has been found in all eukaryotes. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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molecules or folded short-hairpin RNA (shRNA) can
induce the specific degradation of complementary mes-
senger RNA [6]. Because of the rapidity and specificity of
its effects, RNAi has been exploited as a promising tech-
nology for the control of important pathogens, including
human immunodeficiency virus (HIV), herpes simplex
virus (HSV) and hepatitis B virus (HBV) [7-9].
Previous studies conducted in our lab and by other
groups have investigated the inhibitory effect of siRNA
on FMDV replication both in vitro and in vivo [10-12].
However, like other RNA viruses, FMDV undergoes
rapid mutation and is antigenically variable. Further-
more, there are seven distinguishable serological types
(A, O, C, Asia 1, SAT 1, SAT 2, and SAT 3) and more than
65 subtypes [13]. Thus, one major issue in establishing
RNAi as a viable approach to combat FMDV is the high
genetic polymorphism exhibited by this virus. Therefore,
the strategy of combining multiple siRNA/shRNA and
designing shRNA that target the conserved regions of the
viral genome has been suggested [14-17]. The non-
structural protein genes of FMDV, such as 3D [18], 2B
[16] and 3C [11], may serve as potential targets of these
shRNAs.
Another crucial issue is the designing of an optimal trans-
fer vector for the delivery of shRNA-expressing cassettes.
Chen et al. [10] demonstrated that the replication-defective
human adenovirus type 5 (rAd5), which expresses antiviral
shRNA, significantly reduced the susceptibility of guinea
pigs and swine to FMDV infection. Cong et al. [12]
showed that an attenuated Salmonella choleraesuis (C500)
vaccine strain carrying an shRNA-expressing plasmid was
capable of inhibiting FMDV replication in vivo. Neverthe-
less, these methods are still limited because the vectors
only work for a short period of time in animals. An alter-
native strategy is to establish a transgenic RNAi system by
breeding genetically modified species. Recent develop-
ments in plants [19] and insects [20] have demonstrated
that heritable RNAi can induce the resistance to some
infectious diseases. In animals, Golding et al. attempted to
produce transgenic cattle that expressed an shRNA that
targeted the prion protein [21]. Wang et al. also reported
some reduction of infectious symptoms in transgenic mice
that expressed a single shRNA against FMDV [22],
indicating the feasibility of this transgenic system.
In this study, we constructed recombinant plasmids
that could simultaneously express two shRNAs that
targeted the conserved regions of the viral polymerase
protein 3D and the non-structural protein 2B. The
piggyBac transposon system was used as the transgenic
vector in the porcine cell line IBRS-2, and up to 100%
inhibition of the FMDV replication was observed in the
resulting transgenic cell lines. This antiviral capacity was
effective against both serotype O and serotype Asia 1FMDV, and it was not directly affected by the transgene
copy number. In addition, after the germ-line micro-
injection of the linearized plasmids, the offspring of two
transgenic mouse lines exhibited enhanced resistance
against serotype O FMDV infection.
Materials and methods
Plasmids, cells, and viruses
All the experiments involving virus challenge in mice were
approved by the animal ethics committee of Lanzhou
Veterinary Research Institute and followed both the
national guidelines for the use of animals in scientific
research and the standard protocol described by the OIE.
The piggyBac transposon plasmid PB[Act-RFP]DS, PB
[PGK-Neo] and the helper plasmid CMV-PBase were
kindly provided by Prof. Xiaohui Wu [23]. IBRS-2 cells
(swine kidney cells) and all of the IBRS-2-derived trans-
genic cell lines were cultured in Dulbecco’s modified
Eagle’s medium (DMEM, Gibco, Carlsbad, USA) supple-
mented with 5% heat-inactivated fetal bovine serum (FBS)
and adjusted to pH 7.4. BHK-21 cells (hamster kidney
cells) were also cultured in DMEM but with 10% FBS.
The cultures were incubated at 37°C with 5% CO2. FMDV
isolates of serotype O/HKN/2002 [GenBank: AY317098]
and serotype Asia 1/Jiangsu/2005 [GenBank: EF149009]
were used for the viral challenge experiments.
Construction of shRNA-coding vectors
The 3D-shRNA-expressing cassette was modified from
the pPOL plasmid, a construct previously generated by
our lab [10]. A revised mouse U6 promoter (mU6) was
PCR-amplified and cloned into pPOL, replacing the
original U6 promoter. The 56-bp 3D-specific shRNA-
coding region inserted after the mU6 promoter was also
modified to 5’-GAGGCCATCCTCTCCTTTGCACGCC
GTGGGACCATACAGGAGAAGTTGATCTCCGT-3’
(sense, corresponding to nt 1225 to 1280 of O/HKN/2002
3D). Finally, the HindIII site after the transcriptional
terminal signal of five T residues was excised by Klenow
(large fragment) treatment and blunt end ligation. A
lacZ-shRNA-expressing cassette was constructed in the
same manner using pLacZ [10] as a control for non-
specific RNAi.
The 2B-shRNA-expressing cassette was driven by a
human H1 promoter (hH1), which was cloned by PCR
amplification from human genomic DNA extracted from
293 T cells with the Axygen Genomic DNA Kit (Corning,
Tewksbury, USA). Inverted repeats representing the 2B-
shRNA or the heterologous NTH21-shRNA were inserted
after the H1 promoter along with the type III RNA poly-
merase terminal signal of the five T residues. The 25-bp
2B-specific shRNA was 5’-CCAGATGCAGGAGGATAT
GTCAACA-3’ (sense, corresponding to nt 57 to 81 of O/
HKN/2002 2AB), which was also rearranged based on
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sequence of the heterologous NTH21-shRNA has been
described previously [24].
The reporter gene cassette of EGFP was obtained by
cloning the mouse phosphoglycerate kinase (PGK) pro-
moter into pEGFP-N1, replacing the CMV promoter.
The resulting pPGK-EGFP-N1 plasmid was digested
with ApaI and AflII. The neo-resistance (Neo-R) cassette
was PCR amplified from pEGFP-N1 along with the
designated terminal restriction enzyme sites.
Combinations of the above shRNA-coding cassettes
and reporter gene cassettes were cloned into the AscI-
HindIII sites between the transposon arms of the
plasmid PB[Act-RFP]DS to obtain the following plasmid
vectors for transgenic modification: PB-EGFP-Neo-
3DshRNA-2BshRNA (PB-EN3D2B, Figure 1A); PB-
EGFP-Neo-lacZshRNA-NTH21shRNA (PB-ENlacZNH21,
Figure 1B), which is a heterologous RNA-interference
control vector; and PB-Neo-3DshRNA-2BshRNA (PB-
N3D2B, Figure 1C). The first two vectors each contained
two loxP sites at the outer edges of their reporter gene
cassettes and were used for cultured cell modification,
whereas PB-N3D2B was used for the preparation of trans-
genic mice.
Analysis of the repression effects induced by shRNA-coding
vectors against target EGFP expression in BHK-21 cells
A DNA fragment corresponding to nt 1204 to 1290 of
O/HKN/2002 3D and nt 37 to 92 of O/HKN/2002 2AB
in tandem was artificially synthesized and inserted into
the SalI-BamHI site of pEGFP-N1 to form the fusion
protein reporter plasmid pEGFP-Target. To analyze the
suppressing effects of the shRNA-coding vectors against
the reporter plasmid, 0.8 μg of pEGFP-Target and 0.2/
0.4/0.8/0 μg of PB-N3D2B were co-transfected usingFigure 1 Schematic diagram of the shRNA-expressing vectors used fo
cassettes that express the 3D-shRNA, EGFP, Neo-R, and the 2B-shRNA betw
Two loxP sites flank the reporter genes. (B) PB-ENLacZNH21, is identical to
been substituted with non-specific shRNA cassettes. (C) PB-N3D2B, contain
gene, which can be digested from the transposon vector for germ-line tran
arrows indicate the primers used to detect the transgenic cell lines or mice
the transgene copy number.Lipofectamine 2000 (Invitrogen, Carlsbad, USA) into the
monolayers of BHK-21 cells in 12-well plates. All of the
transfection systems were supplemented up to 1.6 μg of
DNA with a piggyBac backbone plasmid PB[PGK-Neo].
After 48 h, the cells were harvested and total RNA was
isolated with an RNeasy Mini Kit (Qiagen, Hilden,
Germany) and then treated with RNase-free DNase for
one hour. The cDNA samples were synthesized by
reverse transcription with Oligo-dT (Takara, Dalian,
China) and then subjected to quantitative PCR (qPCR).
The fusion GFP expression levels were detected using
the primers listed in Table 1, with β-actin as the refer-
ence gene.
Preparation and identification of monoclonal transgenic
cell lines
IBRS-2 cells were seeded in 24-well plates, and 0.2 μg of
plasmid PB-EN3D2B (or PB-ENlacZNH21) together
with 0.2 μg of the transposase-expressing helper plasmid
CMV-PBase were co-transfected into each well using
Lipofectamine 2000. After 24 h of incubation, the cells
were digested and approximately 1/20 to 1/40 of the
cells in a single well were added to a 10-cm plate
containing DMEM and 5% FBS. On the following day,
the medium was replaced with DMEM containing 5%
FBS and 300 μg/mL G418 (Sigma-Aldrich, St.Louis, USA).
After 12–14 days of incubation, monoclonal colonies were
individually collected with clone cylinders and transferred
to 48-well plates. The genomic DNA of each monoclonal
cell line was extracted using an Axygen Genomic DNA
Kit. The primer pairs PBL1F/PBL1R and PBR1F/PBR1R,
which amplify specific fragments in the left and right
transposon arms, respectively, were used to identify the
transgenic cell lines (Table 1 and Figure 1A). PCR tests
using the primers PBase-F and PBase-R were performedr transgenic modification. (A) PB-EN3D2B, with a tandem array of
een the left and right transposon arms of the piggyBac transposon.
PB-EN3D2B except that the two FMDV-targeting shRNA cassettes have
s the fragment of two antiviral shRNA cassettes and the Neo-R reporter
sgene; the transposon arms are not shown. The pairs of small black
. White bars indicate the PCR-amplified fragments used to determine
Table 1 The PCR primers used for detection and qPCR of
transgenic cells and mice
Name Sequence Function
GFP-F GGTCTTGTAGTTGCCGTCGT Quantitate GFP in
BHK-21 cells
GFP-R TCGTGACCACCCTGACCTAC
h-actin-F CACGCAGCTCGTTGTAGAAG Quantitate β-actin in
BHK-21 cells
h-actin-R AGGACTCGTACGTGGGTGAC
PBL1-F CAACATACGAGCCGGAAGCATAAA Detect PBL in
cell lines
PBL1-R TAACAGAATCTTGACCTTGCCACA
PBR1-F AGTCAGTCAGAAACAACTTTGGCACA Detect PBR in
cell lines
PBR1-R ACGAATAGGTGGCCTATGGCATTATTG
PBase-F GCCACCATGGGATGTTCTTTAG Detect transposase
in cell lines
PBase-R GTACTCAGAAACAACTTTGGC
Q-PBR1-F TACGCATAAACGATGACG Quantitate copy
number in cell lines
Q-PBR1-R CAAACTAAAGGCGGAGTG
Neo-2B-F TGACCGCTTCCTCGTGCTTT Detect transgenic
mice
Neo-2B-R TGGGTGTTCCCGCCTAGTGA
3D-Neo-F ATCCGACGCCGCCATCTCTA Detect transgenic
mice
3D-Neo-R CGGAGAACCTGCGTGCAATC
NR-F CGTTTCGCATGATTGAACAAGAT Quantitate copy
number in mice
NR-R GTGCCCAGTCATAGCCGAAT
GI-F GGTGGTGAATACCATGTACAAAGCT Quantitate GAPDH
as reference in mice
GI-R CCAACACCCCCAGTCATACG
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transposase had not been inserted. The resulting MTCL
generated from the plasmids PB-EN3D2B and PB-
ENlacZNH21 were named IB-3D2B and IB-lacZNH,
respectively.
To detect the transgene copy numbers in the MTCL,
genomic DNA samples were used as templates for qPCR
with the primers Q-PBR1-F and Q-PBR1-R to amplify a
229-bp fragment of the right transposon arm (PBR). The
results were normalized to the absolute amount of DNA
in each sample.
Production and selection of transgenic mice
For germ-line transgenesis, female Kunming White (KM)
mice that had been pretreated with PMSG (pregnant mare
serum gonadotropin) and HCG (human chorionic gona-
dotropin, Sigma-Aldrich) were mated with male KM mice
as fertilized egg donors. The 2.5-kb AscI-HindIII fragment
of the plasmid PB-N3D2B (Figure 1C) was purified and
diluted to a concentration of 2 ng/μL. After the male
pronucleus was microinjected with the DNA solution, the
eggs were transferred into the oviducts of pseudopregnant
KM females to generate transgenic mice.
Tail tips (approximately 1-cm long) were collected
from all of the mice offspring at 3 weeks of age and
incubated at 56°C in a buffer of 50 mM Tris (pH 8.0),100 mM EDTA, 100 mM NaCl, 1% SDS and 0.5 mg/mL
protease K. After 3 h, the mouse genomic DNA was
isolated by phenol-chloroform extraction and ethanol
precipitation. The DNA samples were then dissolved in
TE (pH 8.0), and the transgenic status of the mice was
examined using PCR amplification with the primer pairs
3D-Neo-F/3D-Neo-R and Neo-2B-F/Neo-2B-R (Table 1
and Figure 1C), which could detect the presence of the
3D and 2B-shRNA cassettes. The transgene copy num-
bers in transgenic mice were examined by qPCR using
the corresponding primers and with GAPDH as the
reference gene. All transgenic founder mice were crossed
with wild-type (WT) KM mice to maintain the descen-
dants as hemizygotes.
Virus challenge in transgenic cell lines
The 50% tissue culture infective doses (TCID50) of FMDV
were calculated using the Reed-Muench formula [25].
Viral suspensions of 106 to 107 TCID50/mL were used for
the experiments. To assess the antiviral capacity of the
MTCL, each of the cell lines was seeded in 96-well plates.
On the following day, 20 or 50 TCID50 of FMDV diluted
in 0.1 mL DMEM without FBS were added to the mono-
layers. After one hour of absorption, the virus dilutions
were removed, and the cells were washed with DMEM
and then incubated at 37°C with 5% CO2. The cytopathic
effects (CPE) were examined microscopically over 3 days.
Supernatant fluids were harvested at various times after
infection, and viral titers (i.e., TCID50) at 24-h intervals
were determined three times in BHK-21 cells.
Virus challenge in transgenic suckling mice
Suckling mice (2 to 3 days old) were inoculated with four
10-fold serially diluted virus solutions (i.e., 10-6, 10-7, 10-8,
and 10-9) in phosphate-buffered saline (PBS) by subcuta-
neous injection in the neck area. The 50% lethal dose
(LD50) was estimated using the Reed-Muench method
[25]. To investigate the antiviral capacities of the trans-
genic mice, hemizygous male mice from transgenic mouse
lines were crossed with WT female KM mice, and the
newborn offspring (with a transgenic ratio of approxi-
mately 50%) were challenged with different doses of
FMDV in 0.2 mL of PBS by subcutaneous injection. Tail
samples were collected from every suckling mouse one
day before the virus challenge. After the 5 days of observa-
tion, the genomic DNA extraction and transgenic-status
differentiation were performed as described above. The
survival rate of the transgenic mice was recorded, and
their non-transgenic littermates were used as controls.
Statistical analysis
GraphPad Prism 5.0 software was used for all the statis-
tical analyses.
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The shRNA-coding vectors effectively suppressed target
fusion GFP protein expression in BHK-21 cells
To identify the interfering effect of the shRNA-coding
vectors, plasmid PB-N3D2B was co-transfected with
pEGFP-Target into BHK-21 cells at different mass ratios
of 0:1, 1:1, 0.5:1, and 0.25:1. The GFP expression of each
sample was determined by qPCR. Figure 2 shows that
when the two plasmids were co-transfected in the massFigure 2 The shRNA-coding plasmid can inhibit the artificial
target gene in BHK-21 cells. The shRNA-coding plasmid PB-N3D2B
was co-transfected with the fusion GFP-expressing plasmid, pEFGP-
Target, at different ratios (0:1, 1:1, 0.5:1, and 0.25:1). The mRNA levels
of GFP were measured by qPCR. (A) One amplification plot of three
separate experiments is shown. The y-axis represents the PCR
relative fluorescence units at the wavelength of 465 to 510 nm. The
cycle number is displayed on the x-axis. (B) Cycle threshold (CT)
values are derived from the amplification profiles shown in panel A.
(C) The suppression ratio of different amounts of PB-N3D2B
compared to the control with no PB-N3D2B (transfection ratio 0:1) is
shown. The data represent the means ± SEM of three
separate experiments.ratio of 1:1, PB-N3D2B was able to inhibit 77.7% of the
artificial target mRNA. As the amount of PB-N3D2B
decreased, the suppression efficiencies of the target
mRNA were 61.2%, and 49.7%, respectively. This response
occurred in a dose-dependent manner compared to the
control with no PB-N3D2B (transfection ratio of 0:1).
Establishment of shRNA-expressing monoclonal transgenic
cell lines
The PB-EN3D2B and PB-ENlacZNH21 plasmid were
integrated into the genome of IBRS-2 cell using the
piggyBac transposon system. Monoclonal colonies with
both G418 resistance and EGFP expression (Figure 3A)
were harvested and developed into monoclonal trans-
genic cell lines (Figure 3B). By PCR confirmation, we
obtained 16 IB-3D2B and 3 IB-lacZNH MTCL. After
monoclonal selection, all cell lines were passaged with-
out G418 at least 10 times before the virus challenges.
The shRNA genes conferred resistance against serotype O
FMDV infection in transgenic cell lines
To evaluate whether the presence of transgenic shRNA
genes correlated with antiviral activity, 6 strains of IB-
3D2B were infected with 20 TCID50 of FMDV O/HKN/
2002. Two strains of IB-lacZNH and normal IBRS-2
cells were submitted to virus challenge at the same time
as controls. The cells were observed every 24 h under a
microscope. Figure 4A shows that all the control cells,
including normal IBRS-2 and the two heterologous
shRNA-expressing IB-lacZNH-1 and IB-lacZNH-3 strains,
exhibited extensive CPE within 24 hpc. The IB-3D2B-1,
IB-3D2B-5, and IB-3D2B-7 cells showed slight CPE at 24
hpc, but they exhibited severe CPE after 48 hpc. However,
the cell line IB-3D2B-2 showed significant resistance to
FMDV with only mild CPE at 48 hpc. The cell lines IB-Figure 3 Establishment of transgenic monoclonal colonies and
the development of MTCL. The shRNA-expressing plasmids PB-
EN3D2B or PB-ENlacZNH21 were integrated into the genome of
IBRS-2 cells using the piggyBac transposon system. Monoclonal
colonies with both G418 resistance and EGFP expression were
selected (A, magnification is 100×). The colonies were then cultured
to generate cell lines. All of the cells expressed EGFP (B, magnification
is 200×). The images were adjusted for contrast and dpi (dot per inch)
to improve their appearance.
Figure 4 Endogenous shRNA in MTCL conferred natural resistance to FMDV infection. Eight cell lines and normal IBRS-2 cells were
challenged with 20 TCID50 of FMDV O/HKN/2002 (A), 50 TCID50 of FMDV O/HKN/2002 (B) or 20 TCID50 of FMDV Asia 1/Jiangsu/2005 (C). At 24
hpc (left column) and 48 hpc (middle column), cells were observed under a microscope. Mock challenged cells from the same cell lines at 48
hpc were used as controls (right column). Normal IBRS-2 cells form an epithelial-like monolayer. These cells round up, separate, and finally
undergo cell lysis (CPE) when infected by FMDV. The MTCL IB32-2 and IB32-3 exhibited significant antiviral capacity with considerable delayed
CPE. IB32-6 had the strongest anti-FMDV capacity and was undamaged by all three challenges. The images were adjusted for contrast and dpi to
improve their appearance, and the magnification for all images is 200 ×.
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ties because no CPE was observed in these cells after
3 days of observation. We also investigated the inhibitory
effect of endogenous shRNA on virus replication by
measuring the viral titers in the supernatants of each cell
culture at 24-h intervals. These results were consistent
with the microscopic observations (Figure 5A). NoFMDV was detected in the supernatants of the IB-
3D2B-3 and IB-3D2B-6 cells. The supernatant viral
titers of the IB-3D2B-2 cells were reduced by 90% at 24
hpc and by 94% at 48 hpc compared to the non-
transgenic IBRS-2 cells (P < 0.001). The other three
transgenic cell lines, IB-3D2B-1, IB-3D2B-5, and IB-
3D2B-7, and the two control cell lines, IB-lacZNH-1
Figure 5 Endogenous shRNA in transgenic cell lines conferred natural resistance to serotype O FMDV infection. Eight cell lines and
control cells were challenged with 20 TCID50 of FMDV O/HKN/2002. Culture supernatants were collected at 24, 48 and 72 hpc, and virus yields
were measured by TCID50 (A). Three of the cell lines with an obvious antiviral ability were further challenged with a higher dose of 50 TCID50 of
serotype O virus. Supernatant virus titers (B) and the relative titer reduction (C) were measured. The data represent the means ± SEM of three
separate experiments. Asterisks indicate the samples that are different from normal IBRS-2 cells at the same time interval as determined by
two-way ANOVA with Bonferroni post-test, *P < 0.05, ***P < 0.001.
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compared with the normal IBRS-2 cells.
To further study the antiviral potential of the MTCL,
the three transgenic cell lines IB-3D2B-2, IB-3D2B-3,
and IB-3D2B-6 were challenged with 50 TCID50 of FMDV
O/HKN/2002, and normal IBRS-2 cells were used as
controls. Microscopic examination revealed that there was
an obvious delay in the CPE development in IB-3D2B-2
and IB-3D2B-3 cells challenged with 50 TCID50 of virus,
whereas the IB-3D2B-6 cells, which had stronger antiviral
activity, failed to develop any CPE after 3 days of observa-
tion (Figure 4B). The virus was not detectable in the
supernatant fluid of IB-3D2B-6 cells. IB-3D2B-2 and IB-
3D2B-3 also showed significantly reduced titers within 48
hpc (at least 95% of reduction, Figure 5B and C).The shRNA genes provided inhibitory effects against
serotype Asia 1 FMDV in the transgenic cell lines
The shRNAs that we applied in this investigation
targeted the conserved regions of the FMDV genome,
which theoretically enabled cross-inhibition of infection
by different FMDV serotypes. To test this capacity, the
MTCL of IB-3D2B-2, IB-3D2B-3, and IB-3D2B-6 were
challenged with 20 TCID50 of FMDVAsia 1/Jiangsu/2005.As shown in Figure 4C and Figure 6, delayed CPE and
reduced supernatant virus titers were found in cell lines
IB-3D2B-2 and IB-3D2B-3. Again, IB-3D2B-6 completely
inhibited viral replication. Thus, the antiviral ability of the
selected cell lines was effective against both serotype O
and serotype Asia 1 FMDV.The shRNA gene copy number does not directly affect
the degree of resistance in the transgenic cell lines
Because the piggyBac transposon system appeared to
randomly integrate DNA fragments into the genome at
multiple sites, we attempted to analyze the correlation
between the antiviral effects and the individual transgenic
statuses of the MTCL. The shRNA gene copy numbers of
the 8 MTCL were determined by qPCR, and the results
are listed in Table 2. The IB-3D2B-3 cells that had the
highest copy number (13 integrations) did strongly inhibit
FMDV replication; however, the IB-3D2B-1 cells with a
copy number of 11 did not display significant inhibitory
effect against FMDV. Likewise, the IB-3D2B-2 and IB-
3D2B-5 cells had similar copy numbers, but their antiviral
capacities were quite different. Furthermore, the IB-3D2B-
6 cells that had the highest anti-FMDV capacity contained
only one copy of the shRNA-expressing genes.
Figure 6 Endogenous shRNA in transgenic cell lines provided
an inhibitory effect to serotype Asia 1 FMDV infection. Three
cell lines, IB-3D2B-2, IB-3D2B-3, and IB-3D2B-6, were challenged with
20 TCID50 of FMDV Asia 1/Jiangsu/2005. Supernatant virus titers (A)
and the relative titer reduction (B) were measured. The data
represent the means ± SEM of three separate experiments. Asterisks
indicate the samples that are different from normal IBRS-2 cells at
the same time interval as determined by two-way ANOVA with
Bonferroni post-test, *P < 0.05, ***P < 0.001.
Table 3 Survival rates of suckling mice from different
transgenic mouse lines challenged with serotype O FMDV




Survival/Total (%) Survival/Total (%)
N3D2B-18 10 0/9 (0) 1/16 (6.3)
6 3/21 (14.3) 3/33 (9.1)
3 7/26 (26.9) 0/27 (0)
N3D2B-81 10 0/9 (0) 0/22 (0)
6 3/11 (27.3) 0/23 (0)
3 7/17 (41.2) 2/9 (22.2)
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transgenic suckling mice after virus challenge
Two lines of transgenic mice, N3D2B-18 (copy number = 1)
and N3D2B-81 (copy number = 2), were used for in vivo
studies to assess the potential anti-FMDV activity of
endogenous shRNA. The suckling mice from the two lines
were first challenged with a relatively high dose of 10
LD50 FMDV O/HKN/2002. Neither of the transgenicTable 2 Correlation between transgene copy numbers
and antiviral capacities of the MTCL.









a: Semi-quantitative analysis of the antiviral capacities: - is negative and similar
to non-transgenic cells; +++ is maximum.lines exhibited significant resistance to FMDV infection
(Table 3). To further evaluate the antiviral capacities of
these transgenic mice, the challenge dosage was
reduced to 3 and 6 LD50. The results are illustrated in
Table 3. When challenged with 3 LD50 of type O
FMDV, 7 out of the 26 transgenic suckling mice
(26.9%) from line N3D2B-18 survived after all 27 non-
transgenic littermates had died (P < 0.01). In the line
N3D2B-81 mice, the survival rate at this dosage
increased from 22.2% in the littermates to 41.2% in the
transgenic mice. Using a challenge dose of 6 LD50,
transgenic suckling mice from line N3D2B-18 showed a
slight increase (14.3% compared to 9.1%) in the survival
rate compared with controls. However, the N3D2B-81
mice showed greater antiviral capacities at this dosage,
and the rate of survival was 27.3% compared to 0% for
the littermates.
Discussion
Although the technique for producing transgenic animals
that express shRNA was first reported in 2002 [26-28], few
studies have explored the prevention of virus replication in
mammals using this strategy. Wang et al. attempted to
generate a transgenic mouse model containing a single
anti-FMDV shRNA gene [22]. Immunohistochemical
assays demonstrated a reduction of the virus in the tissues
of infected adult primary transgenic mice. Another report
by Wang and Wu discussed the antiviral potential of
shRNA-expressing cells and primary cells from transgenic
bovine fetuses made by lenti-virus insertion [29]. However,
no reports have evaluated whether the transgenic FMDV-
susceptible animals and their transgenic offspring were
capable of resisting to viral infection. In this study, we
constructed plasmids that simultaneously encoded two
shRNAs that targeted conserved regions of the FMDV
genome. The results demonstrated that the plasmid PB-
N3D2B was able to effectively suppress an artificial target
in vitro, and transgenic modification with these plasmids
provided strong antiviral capacity in repeatedly passaged
cell lines and enhanced resistance against FMDV infection
in offspring suckling mice. Our present experimental data
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http://www.veterinaryresearch.org/content/44/1/47suggest that transgenic RNAi is worthy of pursuit as a
strategy for producing animals resistant to FMDV.
The method of combining multiple conserved region-
targeting siRNA/shRNA has been the preferred antiviral
strategy because one shRNA can complement the other,
with the added benefit of potentially suppressing
mutated or heterologous viruses [16,30]. Notably, there
is evidence that the co-expression of multiple shRNAs
from a single construct appears to be more effective
than simply mixing single shRNAs [17]. In this investiga-
tion, we simultaneously expressed a 25-bp 2B-targeting
and a 56-bp 3D-targeting shRNA. The 2B gene is
involved in membrane rearrangements that are required
for viral RNA replication and capsid assembly [31]. The
3D gene encodes the RNA-dependent RNA polymerase,
the fundamental protein that conducts viral genome rep-
lication [32]. We did not employ a typical 19-bp shRNA
because the 56- and 25-bp shRNA-corresponding
sequences in different serotypes of FMDV were highly
conserved, and these longer shRNAs had strong anti-
FMDV effects [10,12]. This phenomenon may be attri-
buted to the potential diversity of the siRNA products
made from long shRNAs by Dicer, which mimics the
combination of multiple shRNAs.
The short half-life of siRNA/shRNA has always been a
challenge for in vivo tests. In most reports, RNAi treat-
ment might be effective only if the injection of siRNA/
shRNA was performed within two days before the virus
inoculation. In particular, the commonly used RNAi
delivery system, recombinant adenovirus (rAd), has
unavoidable shortcomings. The rAd-derived non-coding
RNA VA1 can be expressed so strongly that it saturates
the exportin-5 pathway, which is necessary for the trans-
port of both foreign shRNA and cellular microRNA
[33,34]. The differential tissue distributions of rAd and
FMDV are an additional complication [35]. In this study,
the MTCL were subjected to two rounds of monoclonal
selection and were passaged at a 1:2 to 1:3 ratio 10 to 15
times before virus challenge, and F3 or F4 transgenic
suckling mice underwent antiviral testing. Due to the
genomic stability of our transgenic products, transgenic
animals express natural resistance and do not require
on-going precautionary inoculations.
The position effect is a major factor that determines
transgene expression levels [36]. Specifically, the expres-
sion of foreign genes is influenced by the chromosome
structure surrounding the integration sites and cis-
acting elements, such as enhancers and insulators. This
effect makes the expression of transgenes unpredictable.
Although we used polIII promoters (U6 and H1) instead
of the polII promoter (for instance, CMV), which is
usually used for foreign protein expression, a similar
phenomenon was observed in our experiments. Assu-
ming that the RNA expression level is positively relatedto the antiviral effect, the capacity of suppressing FMDV
is the accumulation of all the integrating sites in the
transgenic cell lines. As for the microinjection method
in mouse experiments, however, foreign gene fragments
tend to integrate into a few sites but with multiple
copies. Once the fate of the entire transgene cluster is
determined by its local position, the copy number and
homozygous/hemizygous status do affect gene expres-
sion [37,38]. In this study, we selected low-copy and
hemizygous transgenic lines to avoid possible genetic
side effects, such as chromosomal recombination and
lethal homozygosity. This selection may partly explain
the relatively limited antiviral capacities of the transgenic
mouse lines. As primary cell selection and nuclear
transfer is the principle technique of breeding large
transgenic animals, locus control regions (LCR) [39] or
artificial chromosomes [40] could be employed as
position-independent delivery methods to elicit more
efficient RNAi expression and to reduce the cost of
selecting effective offspring.
In conclusion, we show that heritable FMDV resistance
can be conferred by two endogenous shRNAs in suscep-
tible cells and animals. To further improve this strategy,
we are currently developing a multiple conserved region-
targeting shRNA gene to confer strong, broad-spectrum
resistance to FMDV infections of different serotypes.
Additionally, novel transgenic methods in combination
with conditional RNAi induction are expected to prevent
side effects in livestock.
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